Analysts See $-0.43 EPS for Advaxis, Inc. (ADXS); Celanese (CE) Has 1.06 Sentiment

December 7, 2017 - By whatsonthorold

Analysts expect Advaxis, Inc. (NASDAQ:ADXS) to report $-0.43 EPS on January, 8.After having $-0.80 EPS previously, Advaxis, Inc.’s analysts see -46.25% EPS growth. The stock decreased 2.05% or $0.06 during the last trading session, reaching $2.87. About 791,112 shares traded. Advaxis, Inc. (NASDAQ:ADXS) has risen 11.01% since December 7, 2016 and is uptrending. It has underperformed by 5.69% the S&P500.

Celanese Corporation, a technology and specialty materials company, makes and sells value-added chemicals, thermoplastic polymers, and other chemical products worldwide. The company has market cap of $14.33 billion. The companyÂ’s Advanced Engineered Materials segment develops, produces, and supplies specialty polymers for automotive and medical applications, as well as for use in industrial products and consumer electronics. It has a 18.48 P/E ratio. The Company’s Consumer Specialties segment provides cellulose acetate flakes, films, and tows for use in filter products applications; food protection ingredients, such as potassium sorbate and sorbic acid for food and beverage industry; Sunett, a sweetener for use in various beverages, confections, and dairy products; and Qorus, a sweetener system designed for low-to no-calorie carbonated and non-carbonated beverages, flavored waters, energy drinks, and milk and dairy products.

Gmt Capital Corp holds 8.48% of its portfolio in Celanese Corporation for 4.11 million shares. Lyrical Asset Management Lp owns 2.94 million shares or 3.93% of their US portfolio. Moreover, Muhlenkamp & Co Inc has 3.63% invested in the company for 122,165 shares. The Georgia-based Covey Capital Advisors Llc has invested 3.08% in the stock. Chase Investment Counsel Corp, a Virginia-based fund reported 66,006 shares.

The stock decreased 0.24% or $0.25 during the last trading session, reaching $105.61. About 1.11M shares traded or 61.56% up from the average. Celanese Corporation (CE) has risen 21.48% since December 7, 2016 and is uptrending. It has outperformed by 4.78% the S&P500.

Ratings analysis reveals 83% of Celanese’s analysts are positive. Out of 6 Wall Street analysts rating Celanese, 5 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. The lowest target is $80.0 while the high is $105.0. The stock’s average target of $93.25 is -11.70% below today’s ($105.61) share price. CE was included in 6 notes of analysts from September 7, 2016. Citigroup downgraded Celanese Corporation (NYSE:CE) on Wednesday, September 7 to “Neutral” rating. On Wednesday, November 30 the stock rating was upgraded by Goldman Sachs to “Buy”. The stock of Celanese Corporation (NYSE:CE) earned “Outperform” rating by RBC Capital Markets on Tuesday, December 13. The stock has “Outperform” rating by Robert W. Baird on Friday, February 17. The rating was initiated by KeyBanc Capital Markets with “Overweight” on Friday, October 7. The rating was maintained by Cowen & Co with “Outperform” on Thursday, December 1.

Analysts await Celanese Corporation (NYSE:CE) to report earnings on February, 7. They expect $1.84 EPS, up 21.05% or $0.32 from last year’s $1.52 per share. CE’s profit will be $249.58 million for 14.35 P/E if the $1.84 EPS becomes a reality. After $1.93 actual EPS reported by Celanese Corporation for the previous quarter, Wall Street now forecasts -4.66% negative EPS growth.

Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Lm-LLO cancer immunotherapies in the United States. The company has market cap of $117.86 million. The Company’s lead product Axalimogene filolisbac, an Lm-LLO immunotherapy product candidate, which completed its Phase II study for the treatment of human papilloma virus associated cancers, including cervical, head and neck, and anal cancer. It currently has negative earnings. The firm is also developing ADXS-PSA, an Lm-LLO immunotherapy product candidate, which is in Phase I/II clinical trials designed to target the prostate specific antigen associated with prostate cancer; and ADXS-HER2, an Lm-LLO immunotherapy product candidate that is in Phase Ib clinical trials used for the treatment of human epidermal growth factor receptor 2 expressing cancers, including human and canine osteosarcoma.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>